Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease

<jats:sec><jats:title>Background</jats:title><jats:p>Biolimus‐eluting stents (BES) have similar efficacy and safety compared with cobalt chromium everolimus‐eluting stents (CoCr‐EES), whereas it is unclear whether the same applies to small vessel disease. We sought compare clinical outcomes between BES and CoCr‐EES in patients with small vessel disease.</jats:p></jats:sec><jats:sec><jats:title>Methods and results</jats:title><jats:p>A total of 1,132 patients treated only with BES (612 patients) or EES (520 patients) in small vessel disease (stent size 2.5‐mm) were retrospectively analyzed. We assessed the cumulative 2‐year incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiac death, myocardial infarction (MI), definite stent thrombosis (ST), and clinically driven target lesion revascularization (CD‐TLR). The cumulative 2‐year incidence of MACE was similar between the two groups (12.1% vs. 11.8%, <jats:italic>P</jats:italic> = 0.77). The cumulative incidence of cardiac death, CD‐TLR, and definite ST were also not significantly different between both groups (3.2% vs. 3.6%, <jats:italic>P</jats:italic> = 0.78; 8.3% vs. 8.4%, <jats:italic>P</jats:italic> = 1.00; 0.33% vs. 0.21%, <jats:italic>P</jats:italic> = 0.66, respectively). After multivariate adjusting, the adjusted risk of BES group relative to CoCr‐EES group for MACE was not significantly different (hazard ratio [HR]: 0.78, 95% confidential interval [CI]: 0.53–1.15, <jats:italic>P</jats:italic> = 0.20). Similarly, no significant difference in the adjusted risks for cardiac death and CD‐TLR were observed between the two groups (HR: 0.62, 95% CI: 0.28–1.37, <jats:italic>P</jats:italic> = 0.24; HR: 0.81, 95% CI: 0.51–1.29, <jats:italic>P</jats:italic> = 0.38).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Two‐year clinical outcomes of BES are similar to those of CoCr‐EES in patients with small vessel disease. The use of BES is acceptable for small coronary artery disease. © 2015 Wiley Periodicals, Inc.</jats:p></jats:sec>